Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.


Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased incidence of squamous cell carcinoma. The genetic correction of autologous hematopoietic stem cells (HSC) with lentiviral vectors constitutes a recent and safe alternative for the treatment of different genetic diseases affecting mature cells from different tissues and/or committed progenitors of the hematopoietic system. One of the key features of FA that make it a unique disease for gene therapy approaches rely on the characteristic proliferation defect that is already evident in the very primitive HSCs. Thus, a marked survival advantage would be expected from corrected HSCs, potentially allowing normalization of hematopoiesis in the absence or after mild conditioning. Difficulties in the collection of sufficient numbers of HSC from FA patients and the use of sub-optimal transduction protocols with gammaretroviral vectors limited the success of FA gene therapy trials conducted 10 years ago in the USA. EuroFancoLen innovative approach is to develop for the first time an efficient and safe gene therapy of FA based on two recent innovations: 1) Discovery of potent HSC mobilizers, such as plerixafor Ans 2) Development of a new lentiviral vector by members of this Consortium, designed as Orphan Drug by the Europan Commission in December 2010: The main objective of this project is, therefore, the development of a multicentric Phase I/II gene therapy trial for FA-A patients, based on the genetic correction of plerixafor+G-CSF mobilized HSCs with the novel lentiviral vector, accompanied by comprehensive and groundbreaking safety and efficacy patient monitoring estudies.


The Spanish cell therapy network (TerCel) is a collaborative research project organized by the Spanish National Institute of Health Carlos III that started in 2003, to promote research in cell therapy and translate the scientific advances in this field to the clinic. Based on a multidisciplinary approach and the interaction and cooperation between 33 groups of basic and clinical scientists across Spain, the main objective of TerCel is to develop new medical therapies based on the use of stem cells for cardiovascular diseases, neurodegenerative diseases and osteo-articular, immune-hematologic and metabolic diseases.


Rare diseases, affecting around 3 million Spanish people, are a social and health problem of the first order. The Centre for Biomedical Network Research on Rare Diseases (CIBERER), a network structure set up at the initiative of the Instituto de Salud Carlos III, pools and furthers the excellence research done in this country with the aim of finding diagnoses and therapies for those affected as quickly as possible.


uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients treat patients with CNS, liver/metabolic and cardiovascular diseases.  We are advancing a focused pipeline of innovative gene therapies and have entered late-stage clinical development in our lead indication, hemophilia B, and have established preclinical proof-of-concept in Huntington’s disease.


CIBERNED is the acronym for "Centro de Investigación Biomédica En Red sobre enfermedades NEuroDegenerativas", a consortium that includes about 60 of the most competitive Spanish groups working on the molecular bases of neurodegenerative diseases. Group leaders are from universities, Spanish Research Council (CSIC) or hospitals from all over Spain, although most of the CIBERNED membres are based on Madrid or Barcelona. Research done by CIBERNED groups has a strong "translational" orientation. Therefore, besides research on pathogenesis and molecular bases of diseases (particularly Alzheimer's and Parkinson's diseases) many of these groups have also a strong focus on the development of new cell and gene therapies. CIBERNED is mainly supported by the Spanish Ministries of Health and Research through the Instituto de Salud Carlos III (Spanish Medical Research Council). 


VCN Biosciences is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for its most advanced candidate, VCN-01.


Praxis Group was founded in 2006 with the aim of offering a solution for the world of pain. This goal was pursued applying the most innovative advances in health science, developing solutions for rare and neglected diseases and regenerative medicine, aiming to improve life quality and patients’ social integration. 

Praxis Pharmaceutical is a company based in Miñano Technological Park, Álava, which operates in Europe and Latin America. The main purpose is to develop, manufacture and market high value added medicines, such as biotechnological sterile lyophilized drugs or micro/nano-metric based solutions.

Praxis is also pioneering cell-based therapy under GMP conditions.

In addition, the R&D team designs highly specialised formulations, such as:

  • Micro- and nanoformulations of innovative medicines
  • Innovative and sustainable solutions for the development and up scaling of pharmaceuticals
  • Advance Therapies for skin regeneration and proof of concept and implementation of genomic editing tools.


VIVEbiotech is a company fully specialized in lentiviral vectors with two areas of expertise: 1. GMP CDMO: GMP Contract Development and Manufacturing Organization specialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing 2. Innovation: VIVEbiotech´ strategy is focused on providing a response to the main hurdles that currently exist within the gene therapy field: a. The need for cost-effective processes. b.The enhancement of the safety profile of viral vectors: worldwide licensed non-integrative episomal stable lentiviral vector (LENTISOMA). VIVEbiotech is currently working with Companies based both in Europe and USA being our main aim being flexible in terms of technical adaptation and slots availability.


Celgene is a global biopharmaceutical company committed to improving the lives of patients with certain types of cancer and other rare incurable diseases.

Our mission is to deliver truly innovative and life-changing drugs for our patients. As a company we work to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer.


In the early 80s’ the establishment of CELBIO represented a true milestone, as this Company quickly became a reference for a number of scientists, giving them a valuable opportunity to gain access to a world of products and equipment in Biotechnology. Later on, this name became familiar also in the Medical and Diagnostic field. This leading approach remained unchanged and possibly improved throughout almost three decades, reinforcing the image of this Company as a reliable and solid partner for the entire scientific community.

At the beginning of the 90s' a sister Company called Euroclone® started its activity with the goal of giving more emphasis to the development of smart ideas which were felt to evolve into nice products to sell. The success was such that in 2009 it was decided to merge the two Companies, and CELBIO was fully incorporated into Euroclone®.

As a matter of fact, Euroclone® nowadays is bringing into the market the “passion” of the early days (since has inherited the Distribution of a panel of well known brands) along with a clear and growing interest in innovative and state-of-the art technologies originated by in-house R&D as well as obtained under private label and OEM agreement with the most qualifi ed manufacturers worldwide.

In other words, Euroclone® continues the tradition of CELBIO, while evolving into a modern supplier of up-to-date and own-branded products, thus reconfirming its position as a key-provider for a number of laboratories and clinics.



Genethon, located in Evry, France, is a non-profit R&D organization dedicated to the design and development of gene therapy treatments for rare genetic diseases from research to clinical validation. It was created by the AFM-Telethon (French Muscular Dystrophy Association) which is its main funding source. Genethon has multiple ongoing programs at clinical, preclinical and research stage for neuromuscular, blood, immune system, and liver diseases. Several of these programs are pursued by Genethon as sponsor, others have been licensed to leading biotech and pharma players in the gene therapy arena such as Audentes, Avexis/Novartis, Gensight Biologics, Orchard Therapeutics, Spark. Genethon was awarded the “Prix Galien France” in 2012.

Sigma Aldrich

A reliable, single-source research partner providing high-quality reagents, technologies and industry-leading service to the life science and high technology markets. Scientific knowledge, innovation, high quality products and reliable delivery that support consistent, predictable results and save researchers time, are our strenght. The Company operates in 35 countries and sales in 160 countries whose objective is to provide excellent service worldwide. Global solutions for research and manufacturing customers, with our brands : · Sigma® Life Science : kits and reagents including genomics, functional genomics, proteomics and cell biology. · Aldrich® Chemistry : organic and inorganic chemicals, building blocks, reagents, advanced materials and stable isotopes. · Fluka® Analytical : Chemicals and reagents for analytical, organic and biochemical and pharmaceutical research and industries. · Supelco® Analytical : Chromatography columns and related tools. · SAFC®: Customized services and manufacturing.


TiGenix is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells. TiGenix´ lead product, Alofisel (darvadstrocel), previously Cx601, received European Commission (EC) approval for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. A global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has recently been acquired by Takeda, a global pharmaceutical company active in gastroenterology.

Charles River Laboratories

Every Step of the Way. As a fully integrated partner, Charles River can support your research at any point along the drug discovery continuum.


ESTEVE is an international pharmaceutical chemical group that focuses its efforts on innovation and excellence in the field of health, striving daily to achieve customer satisfaction and to contribute to the well-being of society. 
ESTEVE's origins date back to 1929, when Dr. Antoni Esteve i Subirana, researcher and entrepreneur, founded the company with a clear vocation: innovating to live better. Since then, thanks to intensive research, an international approach and an active policy of strategic alliances, ESTEVE has established itself as a leading business group in the area of health.


Histocell is a biopharmaceutical company, part of Noray Biosciences Group, for regenerative medicine, developing cell therapy products and novel medical devices for human health. Histocell’s technology is based in the use of adult mesenquimal stem cells (AMSC) applied alone or in combination with new generation biomaterials, which allow to consolidate its position in the development of tissue engineering and advanced therapies drugs


Mafesyster, empresa suministradora de equipos de investigación, control de calidad y Protección Radiologica . Distribuidora exclusiva y Servicio de Asistencia Técnica Autorizado en España de los Irradiadores biólogicos de animales para investigación marca J.L. Shepherd & Associates de centros de Investigación españoles:


CBM (Centro de Biología Molecular de Madrid)   

CNIO(Centro Nacional de Investigaciones Oncológicas de Madrid)

IBM(Centro de investigaciones Biomédicas de Madrid)                  

CIBM(Centro de investigaciones Biomédicas de Granada)

IBIS (Instituto de Biomedicina de Sevilla):

FJC (Fundación Joseph Carreras) – Facultad de medicina de la Universidad de Barcelona

CNIC (Centro Nnal de Invs. Cardiovasculares de Madrid)